Skip to main content
logo
Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
8.48
-0.12 (-1.40%)
At close: Aug 28, 2026, 4:00 PM EDT
8.60
+0.12 (1.42%)
After-hours: Aug 28, 2026, 7:57 PM EDT

Xeris Biopharma Holdings Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-17.170.55-54.84-62.26-94.66-122.73
Depreciation & Amortization
12.8112.6912.6313.1612.671.88
Other Amortization
3.513.373.012.211.560.96
Loss (Gain) From Sale of Assets
----0.24-
Loss (Gain) From Sale of Investments
---0.75-1.260.180.41
Stock-Based Compensation
28.1222.3718.3610.7212.1611.38
Other Operating Activities
30.78--6.57-3.290.110.7
Change in Accounts Receivable
-5.06-10.64-1.22-8.37-13.37-6.24
Change in Inventory
-16.75-19.29-8.78-14.8-7.47-7.42
Change in Accounts Payable
4.83-0.07-9.616.96-4.325.53
Change in Other Net Operating Assets
15.5319.6310.799.92-9.9919.98
Operating Cash Flow
56.6128.63-36.98-47.02-102.89-95.54
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.94-0.7-0.87-2.26-0.52-1.09
Cash Acquisitions
-----38.47
Investment in Securities
--5.75-3.7434.9960.58
Investing Cash Flow
-0.94-0.74.88-634.4697.96

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--50-146.21-
Long-Term Debt Repaid
-----43.5-
Net Debt Issued (Repaid)
--50-102.72-
Issuance of Common Stock
25.9222.271.730.5830.8427.84
Repurchase of Common Stock
-19.23-10.88-3.73-1.01-0.47-0.53
Other Financing Activities
---11.83-1.19-5.61-0.05
Financing Cash Flow
6.6911.3936.17-1.61127.4727.25

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
------0
Net Cash Flow
62.3639.324.07-54.6459.0429.67

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
55.6727.93-37.85-49.29-103.42-96.62
Free Cash Flow Growth
------
Free Cash Flow Margin
16.60%9.57%-18.64%-30.07%-93.80%-194.84%
Free Cash Flow Per Share
0.330.16-0.26-0.36-0.76-1.22
Levered Free Cash Flow
52.4525.97-31.62-19.62-65.85-28.19
Unlevered Free Cash Flow
66.640.77-15.57-5.2-58.6-24.67

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
24.7627.1226.9527.6910.867.29
Change in Working Capital
-1.44-10.36-8.82-6.29-35.1511.85
SEC Filings: 10-K · 10-Q